White blood cell transfusions

Schwarzenberg, L; Mathe, G.; Grouchy, De; Nava, De; Vries, M. J. De; Amiel, J. L.; Cattan, Anat; Schneider, M; Schlumberger, Jean

doi:10.1097/00007890-196607000-00037

Cited by 8 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The salutary effects of continued division by CML myeloid precursors has been noted by others [6,8]. Some centers however routinely irradiate these CML preparations [20,2 11 because of concern about graft versus host disease (GVHD).…”

Section: Discussionmentioning

confidence: 99%

Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia

et al. 1983

View full text Add to dashboard Cite

Leukocyte transfusions from patients with chronic myelogenous leukemia (CML) and elevated WBC counts were given to 14 patients with acute leukemia for the treatment of 16 infectious episodes. The WBCs were not irradiated to determine if engraftment with production of granulocytes would occur following infusion of immature myeloid elements. No recipient was alloimmunized by clinical and serologic criteria. High leukocyte yields were obtained using a variety of differential centrifugation techniques with a mean WBC yield/transfusion of 95 X 10(9) (range 19-275). A mean of 2.5 transfusions (range 1-11) were administered/recipient with a mean total dose of 235 X 10(9) WBC/transfusion episode (range 50-590). Seven patients had granulocyte counts greater than 500/microliters for four or more days (range 4-11 days) following the last transfusion. Ph1 chromosomes were documented in 2 of 4 patients tested 2-8 days following transfusion. Leukocyte alkaline phosphatase scores were increased (greater than 150) in 5/5 recipients tested post-transfusion demonstrating that production of this enzyme can be induced in CML granulocytes. Except for one severe transfusion reaction, there were no significant side effects and no recipient developed signs of graft versus host disease. All patients with sustained increments demonstrated rapid clinical improvement including 3 severely infected, poor risk patients undergoing initial induction therapy. These 3 patients all achieved complete remission with no evidence of the Ph1 chromosome. Because of the high dose of WBC which can be collected and the salutary effect of continued leukocyte production, CML WBC may be the preparation of choice for selected, non-alloimmunized, severely infected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia

et al. 1983

View full text Add to dashboard Cite

show abstract

“…The chief problem was the lack of techniques for obtaining sufficient cells from the blood of normal individuals to substantially raise the blood granulocyte counts (18). This problem led numerous investigators to study the use of patients with chronic myelogenous leukemia (CML) as leukocyte donors (19)(20)(21). Clinical trials suggested that leukocytes could reduce fever and favorably influence the course of infections in leukopenic subjects.…”

Section: Discussionmentioning

confidence: 99%

“…They were chosen because of previous experience with the effects of total body irradiation on these dogs (10) and because dogs of this size could be easily handled. The dogs used as leukocyte and platelet donors were English-American foxhounds, weighing [20][21][22][23][24][25][26][27][28][29][30] kg. These animals, entirely unrelated to beagles, were chosen as blood product donors because of their large size and docile temperament.…”

Section: Methodsmentioning

confidence: 99%

Granulocyte Transfusion Therapy of Experimental Pseudomonas Pneumonia

et al. 1974

View full text Add to dashboard Cite

“…Anfangs wurden Granulocyten durch Plasmapheresetechniken aus Spenderblut konzentriert; um quantitativ bessere Ausbeuten zu erzielen, wurden vor allem Patienten mit chronisch myeloischer Leukfimie (CML) mit hohen peripheren Granulocytenzahlen als Spender herangezogen [37,77,84]. Die Entwicklung des NCI-IBM-Blood Cell Separators [14,38] erlaubte es, Granulocytenkonzentrate durch Differentialzentrifugation in einem geschlossenen System mit kontinuierlichem Blutflul3 zu sammeln.…”

Section: Techniken Der Granulocytengewinnungunclassified

Supportive Therapie der Knochenmarksinsuffizienz Technische, immunologische und klinische Entwicklungen

1975

View full text Add to dashboard Cite

Supportive care with blood component transfusions has greatly improved prognosis in patients with bone marrow failure. This progress has made possible by newly developed techniques for separation of blood cells and by a better understanding of the antigenicity of human blood cells and of immunologic reactions following their transfusion. Transfusion of white cell and platelet-poor red cell preparations prevent alloimmunization to leukocyte and platelet-bound alloantigens, or non-hemolytic transfusion reactions in already alloimmunized patients. Alloimmunization can be circumvened and effective long-term platelet support to thrombocytopenic patients can be provided by matching donor and recipient for HL-A antigens. The place of granulocyte transfusion in clinical therapy has yet to be defined, although their usefulness in infected granulocytopenic patients is suggested by the few studies reported so far.

show abstract

White blood cell transfusions

Cited by 8 publications

References 0 publications

Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia

Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia

Granulocyte Transfusion Therapy of Experimental Pseudomonas Pneumonia

Supportive Therapie der Knochenmarksinsuffizienz Technische, immunologische und klinische Entwicklungen

Contact Info

Product

Resources

About